NCT07912840
Bioequivalence Study Between YHP2508B and YHR2602 in Healthy Subjects
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Area under the plasma drug concentration-time curve [AUCt]
Timeframe: 0-72 hours
Maximum plasma concentration [Cmax]
Timeframe: 0-72 hours
Secondary (4)
Area under the plasma drug concentration -time curve from 0 to infinity [AUCinf]
Area under the plasma drug concentration-time curve/Area under the plasma drug concentration-time curve from time 0 to infinity [AUCt/AUCinf]
Time of peak concentration [Tmax]
Terminal phase of half-life [t1/2]
Arms and interventions
A(RTRT)Experimental
22 subjects, Cross-over, Single dose YHR2602 on period 1 and 3, Single dose of YHP2508B on period 2 and 4.
B(TRTR)Experimental
22 subjects, Cross-over, Single dose YHP2508B on period 1 and 3, Single dose of YHR2602 on period 2 and 4.
Drugs: YHP2508B, YHR2602
Sites
1 site in 1 country
- Gimpo Woori HospitalGimpo-si, South Korea